ConnectiveRx was formed in late 2015 by bringing together PSKW, pioneers in affordability solutions, and PDR, innovators in advanced adherence communications products. We continue to be the home of the PDR, trusted by healthcare professionals to deliver credible drug information for over 70 years. ConnectiveRx brings industry leadership from pharma services, e-prescribing network services, retail pharmacy and commercial payers to deliver affordability and adherence solutions excellence. We work with over 150 pharmaceutical manufacturers and serve hundreds of brands at all stages of the product lifecycle. We connect patients, prescribers and pharmacists to power the connective medication journey.
Our market-leading expertise in designing, implementing and optimizing affordability solutions has helped millions of eligible patients
Our connected health communications network reaches more than 800,000 prescribers, over 77,000 pharmacists and approximately 190 million patients
Our advanced analytics services analyze our 2 billion+ annual prescription and affordability transactions to provide clients with information to design, optimize and manage programs throughout the lifecycle of the brand
We help brands introduce new products and grow their markets by creating awareness and demand. Behavior-informed messaging and targeted acquisition programs find the right patients and help them get started on therapy.
We connect your brand with prescribers, pharmacists and patients before, during and after healthcare encounters both inside and outside of EHR and pharmacy clinical workflow to support product availability and patient access.
Introducing your brand to healthcare professionals (HCPs) and patients across channels
Reach more than 300,000 active prescribers within their EHR
Inform over 800,000 prescribers and 77,000 pharmacists via email
Communicate with more than 100,000 prescribers via mobilePDR
Deliver personalized education to over 190 million patients via their prescribers and pharmacists
We help brands increase access to therapies for eligible patients by providing the means to make medications more affordable both at the pharmacy counter and via buy-and-bill reimbursement services. We foster uptake of affordability offers by communicating with prescribers, pharmacists and patients through multiple channels including pharma representatives, EHR e-prescribing, text-to-patient, online access and pharmacy dispensing workflow systems. We provide data-driven insights to help design, manage and optimize messaging and affordability programs.
Ensuring your brand is accessible to healthcare professionals (HCPs) and eligible patients across channels
Over 791,000 prescribers have used ConnectiveRx affordability programs
First-fill rates increased by 4% to 6% with ConnectiveRx messaging and affordability programs
A recent ConnectiveRx adherence study of over 1.3 million patients showed patients using coupons filled an average of 8.9 scripts vs. 5.0 scripts for non-coupon patients
We help brands at all stages of the lifecycle to drive medication adherence. We start by engaging the prescriber and help motivate patients to fill their prescriptions by delivering personalized information in their prescriber’s office, in the pharmacy, at home and beyond to improve compliance and persistency. We reconnect with lapsed patients in the pharmacy and at home to restart therapy. The utilization of dispensed and refill data from our connected network allows for personalized messaging to support treatment based on the patient’s adherence status.
Encouraging patients to stay adherent to your brand by providing motivation and access tools at the right time
Demonstrated to increase overall prescriptions by 2% to 5% or more after the first fill
Send personalized refill and restart education from the pharmacy to patients at home
Deliver personalized education with drive-to-fill and refill messages to over 190 million patients via their prescribers and pharmacists
We utilize advanced analytic tools and current behavioral information from our connected network to plan, manage and optimize communication and affordability programs all along the medication journey. These proprietary tools along with market intelligence and deep therapeutic expertise allow us to deliver unmatched insights and consultation. Our business intelligence platform enables users to quickly consume, analyze and react to the key factors that impact their business through a number of smart visualizations and interactive reports.
Providing current program performance and actionable analytics:
Program, offer and channel optimization
Advanced analytic services
Client reporting and advanced insights portal
ConnectiveRx drives innovation in patient access and prescriber engagement. We connect patients, prescribers and pharmacists in workflow and beyond to power the connective medication journey. Learn from the opinion leaders at ConnectiveRx, the go-to people in their fields of expertise, who inspire us with their innovative ideas.
Optimizing brand access strategies with wrap-around prescriber messaging: Augment copay program success through targeted communication
Lack of access to copay programs and lack of knowledge of current offers can undermine HCPs’ confidence in prescribing their brand of choice
Prescribers want current copay program information in their EHR when prescribing, and want to be able to give copay program information to their patients (both print and digital)
Receiving information about patients’ use of copay programs gives prescribers more confidence in the brand and copay program
Boost prescriber knowledge and confidence using in-EHR formulary-status messaging: Informing prescribers at the point of prescribing
In a recent survey of prescribers, more than half said that they regularly revise prescriptions due to unexpected formulary issues
78% of prescribers reported that receiving brand formulary messages in the EHR boosts confidence in prescribing a brand
When presented with information on medication alternatives that have better formulary status, 91% of prescribers indicated they would consider prescribing the alternative
Copay coupon distribution channels: effectiveness and preference: seeking a deeper understanding of copay offer delivery
Tangible plastic or paper cards are now just one of the many valuable copay offer delivery channel options
Prescribers and patients welcome in-EHR copay offers
Both tangible and digital coupons produce relevant adherence benefits
Two ways to reimagine email communications to healthcare professionals: Case studies reveal impact of PREVIEW and FROM field
PREVIEW is powerful: traditional email open rates underestimate readership and impact
The FROM field matters: it evokes a user’s perception of the sender and can reveal preferences
Prescribers' focus on patient out-of-pocket drug cost: Recognizing the benefits of offering copay support
Most prescribers are sensitive to patient out-of-pocket drug costs
Brands with copay coupons enjoy 6X more support than those without copay coupons
Selection of brands with coupons vs. those without coupons varies by disease state
Prescribers' response to drug affordability and managed care challenges: Recognizing the benefits of offering multi-channel copay support
78% of prescribers alter their choice of brands at least weekly due to affordability concerns, and 70% do so weekly due to prior authorization or step therapy edits
80% agree that copay coupons are an effective affordability tool, and 72% say coupons support their ability to prescribe where prior authorization or step therapy edits would otherwise limit use
50% of prescribers face weekly obstacles preventing them from giving patients coupons
Common coupon-access obstacles include "not offered on enough brands," "activation required," "absence in e-prescribing module," and "depleted stock of printed coupons"
Multi-channel delivery of copay coupons is desired by more than half of prescribers
Prescribers' expectations of specialty pharmacy services: Identifying steps specialty pharmacies can take to bolster their position
Healthcare professionals highly value specialty pharmacy patient services, especially access and affordability support
Healthcare professionals' knowledge of available patient services (especially financial assistance) influences their choice of specialty pharmacy
77% of healthcare professionals report that less than half of their specialty prescriptions are filled at specialty pharmacies
ConnectiveRx copay programs' impact on medication adherence: A detailed analysis of >1.3 million patients
By month three, 71% of copay coupon users were on therapy, vs. 45% of non-users
Copay coupon users filled prescriptions 50 days faster by the sixth fill
Copay coupon users filled nearly twice as many prescriptions
Program ROI averaged 7.3X
Providing feedback to prescribers regarding patients' use of copay programs: A new opportunity to build prescriber confidence in branded products and their affordability programs
Healthcare professionals want feedback on patients' copay program use, savings and impact on adherence
Knowing that copay programs work for their patients instills healthcare professionals' confidence in both the brand and the copay program
Healthcare professionals who receive such feedback are more likely to recommend a brand's copay program to their patients
Prescribers' focus on patient out-of-pocket drug cost: Recognizing the benefits of offering copay support
Download infographic to discover the three core recommendations from this research.
87% of prescribers consider patient out-of-pocket drug cost when selecting initial prescription
Brands with a copay coupon enjoy 6X more support than brands without
Influence of coupon availability varies by disease state
Five imperatives for coupon and copay program success: A compendium from the thought leaders at ConnectiveRx
With a majority of covered workers now facing a tiered cost-sharing formulary for prescription drugs, patient out-of-pocket costs are more burdensome than ever. It's no surprise then, that coupon and copay programs have become standard promotional resources for both small-molecule and large-molecule pharma brands.
But today's copay programs require careful planning and a serious investment of resources. What's more, they are often implemented in competitive markets where success is never a guarantee. It's not easy to get everything right.
Through our experience managing hundreds of coupon and copay programs, the ConnectiveRx team has identified "Five Imperatives for Coupon and Co-Pay Program Success." If you can get these five right, you should be well on your way to winning!
The articles in this compendium provide important insight into the five imperatives and how to accomplish them. All have been reproduced with permission from PM360.
Introducing the Connective Medication Journey: This journey creates an actionable adherence model for brand teams
Using this new model as a starting point, brands can begin to build a profile of consumers based on demographics, EHR history, pharmacy interaction and more. With that profile in hand, brands can advance the medication journey by interacting with the prescriber, pharmacy, and consumer at multiple touchpoints.
Brands can take definitive steps to inform and motivate consumers and prescribers, educate pharmacists to help activate the consumer journey, support consumers with full-service copay programs, and engage consumers through omnichannel media. Ultimately, these contacts should be integrated in order to deliver the right communication to the right stakeholder via the right channel at the right time. A brand team that effectively engages key stakeholders in this manner can expect to see real progress toward better adherence.
This article has been reproduced with permission from PM360.
Reduce patient out-of-pocket costs: Ensuring patients can afford your medication is the first step to improving medication adherence
Lower cost = Higher persistence
Lower cost = Faster speed to fill
Lower cost = More prescriptions
What's a brand team to do with this information? Download this article to read more.
This article has been reproduced with permission from PM360.
Introducing ConnectiveRx: We simplify how people get and stay on medications by providing information, savings and access
Power of the ConnectiveRx network
Power of connected analytics
The ConnectiveRx Medication Journey
What we do better
Patient Copay Inform: A ConnectiveRx solution to enhance brand affordability programs and help increase adherence
Is your copay program working overtime to help patients adhere? With ConnectiveRx Patient Copay Inform, it will.
About Patient Copay Inform
Adherence needs improvement
Patients using coupons filled prescriptions 50 days faster by the sixth fill
Copay coupon patients fill more prescriptions vs. non-copay coupon patients
Prescriber Copay Inform: A ConnectiveRx solution to enhance brand affordability programs and help increase adherence
Do prescribers give your brand’s copay program enough credit? With ConnectiveRx Patient Copay Inform, they will.
About Prescriber Copay Inform
How copay plus messaging fills the gaps, reinforces through education and closes the loop
Patient savings drive prescriber brand selection
PDR by ConnectiveRx: In response to today's growing digital needs, PDR has become the Prescribers' Digital Reference
For over 70 years, PDR has inspired credibility and trust
PDR is the leading recognized drug resource, used by 84% of prescribers
Healthcare providers will continue to see PDR in its digital formats
PDR by ConnectiveRx delivers clinical education via email to over 800,000 prescribers and 77,000 pharmacists
PDR by ConnectiveRx keeps 100,000 prescribers informed via the proprietary drug information app
Mr. Totonis is Chief Executive Officer.
Previously, Mr. Totonis was the President and CEO of Surescripts. Under his leadership, Surescripts became the nation’s largest e-prescribing and clinical information network connecting physicians, pharmacies, PBMs, EMRs / EHRs, hospitals and HIEs.
Mr. Totonis joined Surescripts from MasterCard Worldwide. He was a senior executive with MasterCard, responsible for the Advisor Services Division globally.
Mr. Totonis started his career with Booz Allen Hamilton’s Strategy Practice. During his tenure with the firm, he was a Senior Partner and served in several executive positions, including Managing Partner of the firm’s Global Financial Services Practice and as a member of the firm’s Executive Management Team.
Mr. Totonis is on the Genstar Capital Strategic Advisory Board, a trustee at Suburban Hospital / Johns Hopkins Medicine and a member of BENS, Business Executives for National Security.
Mr. Breakiron is Chief Financial Officer responsible for financial forecasting, planning and analysis, business operations accounting and reporting, and tax and financial evaluation for new and continuing programs.
Previously, Mr. Breakiron served as Chief Accounting Officer for SunGard Data Systems. Prior to joining SunGard, he served as Senior Vice President and Chief Accounting Officer of Lender Processing Services (LPS). In this capacity, Mr. Breakiron oversaw the company’s accounting, financial reporting, financial planning and analysis, treasury, tax, procurement and vendor risk management functions.
Prior to joining LPS, Mr. Breakiron was Senior Vice President of Financial Planning and Analysis for Fidelity National Information Services and before that, he worked as Senior Vice President and Controller of International Card Services for Certegy, Inc.
Mr. Breakiron is a certified public accountant and holds a Bachelor’s and Master’s degree in Accounting from the University of Florida.
Ms. Broder is General Counsel and Chief Privacy and Compliance Officer and oversees all legal matters, compliance and privacy, and federal and state legislative and regulatory developments.
Ms. Broder joined ConnectiveRx from Surescripts, where she served as the head of Human Resources. Before leading the Human Resources function at Surescripts, she served as an Associate General Counsel, providing policy analysis, strategic advising and legal direction in various areas including e-prescribing and the exchange of clinical health information, HIPAA, HITECH and meaningful use.
Ms. Broder joined Surescripts from McDermott Will & Emery LLP and Husch Blackwell Sanders where she was a member of the firm’s Health Law Departments. There, she advised a wide range of healthcare clients, including healthcare providers, hospitals, AMCs and pharmaceutical companies, on compliance with federal and state laws involving certifications, corporate matters, privacy and security, and fraud, waste and abuse.
Ms. Broder earned her JD, cum laude, from Creighton University, School of Law.
Ms. Gallagher is Chief People Officer and leads all our people programs and initiatives. She is responsible for attracting and retaining talent, rewarding and recognizing our team members and all Human Resource policies and practices.
Prior to joining ConnectiveRx, Ms. Gallagher led the development of the Human Resource function for the manufacturing division of Dendreon Corporation. She played a key role in a major expansion of the business to support the conversion from clinical manufacturing to commercial manufacturing.
Ms. Gallagher’s diverse Human Resource background spans the pharmaceutical, telecommunications and business services industries where she partnered with senior leaders at Bayer HealthCare Pharmaceuticals, Level 3 Communications and ADP. She has significant experience in acquisitions and divestitures, major growth initiatives, restructurings and building and developing teams.
Mr. Huonker is Chief Operations Officer and leads program execution, customer service, claims processing, retail pharmacy network development and messaging operations.
Prior to joining ConnectiveRx, Mr. Huonker was the Chief Operational Risk Officer at Walgreens. In the 20 years that he spent at Walgreens, Mr. Huonker held a variety of senior executive roles including SVP of Pharmacy Services, SVP of Healthcare Innovation and Health Information Technology, SVP of Global Projects and Strategic Sourcing, SVP of Process Improvement and Cost Innovation and Vice President of Store Operations.
As SVP of Pharmacy Services, Mr. Huonker had responsibility for pharmacy activities within all the retail stores and as Vice President of Store Operations, had responsibility for four markets including Puerto Rico. He is a past co-chair of the Board of Directors for Surescripts and continues to serve on the board of Webster University School of Business and Technology.
Mr. Huonker holds a Bachelor of Science degree from St. Louis College of Pharmacy and an MBA from Webster University.
Mr. Ratliff is President and Chief Commercial Officer leading business development, product management, provider network development, advanced analytics, product marketing and market research.
Prior to joining ConnectiveRx, Mr. Ratliff was a Managing Director in Accenture’s Health and Public Service Practice and served as the North America Lead for Digital Health. There, he was responsible for defining and executing Accenture’s strategy to transform healthcare clients into digital businesses. Prior to that, Mr. Ratliff was the Global Lead for Connected Health Services where he developed a new practice that assisted healthcare clients around the world to improve clinical integration and develop platforms for new care delivery models.
Before joining Accenture, Mr. Ratliff was the founding Chief Operating Officer for Surescripts where he led the efforts to establish the largest national network for e-prescribing in the world. Earlier in his career, he held various management positions at IBM, VHA and Healthvision.
Mr. Ratliff graduated from the University of Oklahoma with a degree in Chemical Engineering. He also holds an MBA from the University of Tulsa. He is a member of the eHealth Initiative Board of Directors.
Mr. Yakimischak is Chief Technology Officer and is responsible for product delivery, systems development, technical operations, security, business analysis and quality assurance.
Prior to ConnectiveRx, Mr. Yakimischak held several executive positions at Surescripts, including Chief Technology Officer, Chief Quality Officer and General Manager. During his tenure at Surescripts, he helped build the network and grow the business by several orders of magnitude. He also pioneered an innovative Quality Management program that drove measurable improvements in clinical quality and safety.
Prior to Surescripts, Mr. Yakimischak held roles in marketing, product management, product development and technology at several companies including Medscape, Medicalogic, JSTOR, Dow Jones and Merrill Lynch.
Mr. Yakimischak holds a Bachelor’s degree in Computer Science from the University of Toronto and an MBA from Johns Hopkins University.
The ConnectiveRx purpose is to simplify how people get and stay on medications by providing information, savings and access. We hire talented, innovative people who want to contribute to helping prescribers, pharmacists and patients by providing education, information and affordability services throughout the patient’s ongoing medication journey.
We are an equal opportunity employer and all qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability status, protected veteran status, or any other characteristic protected by law.
This form is intended for business inquiries, newsletter requests, privacy questions related to this website, and general questions about ConnectiveRx only. We are not able to respond to individual questions about specific programs or offers. Do not submit your prescription or other personal medical information here; for individual assistance, please contact our customer service team at 908-809-6100.